Channod Biopharmaceuticals Channod Biopharmaceuticals

0717—6855399
CN

Channod Biopharmaceuticals

imgboxbg

News

Check category
your location:
Homepage
>
News

Character story | Lu Dongan: rushing to the smoke-filled entrepreneurial market

In 2012, when Lu Dongan was 30 years old, he decided to leave Wuhan Wanzhi Chemical and Pharmaceutical Co., Ltd., where he had worked for nearly five years, to start a new journey - entrepreneurship.
Click to see more
21
2022-01

Cell sub-journal: Reveals enhanced macrophage ability to kill cancer cells

Time of issue: : 2022-01--21
January 21, 2022 /Bio Valley BIOON/---Blocking the inhibitory checkpoint SIRPα-CD47 can promote the phagocytosis of cancer cells by macrophages, which is a promising approach in anticancer therapy. Efficient phagocytosis is strictly dependent on the co-engagement of prophagocytic receptors—Fc receptors (FcR), integrin CD11b or SLAMF7—with ligands on the surface of cancer cells. ​
查看详情 查看详情
21
2022-01

Endometrial cancer "immune + targeted" therapy! Merck/Eisai Keytruda+Lenvima: Significantly prolong survival!

Time of issue: : 2022-01--21
Keytruda+Lenvima is an "immune + targeted" combination therapy that has been approved to treat 2 different types of cancer: endometrial cancer (EC), renal cell carcinoma (RCC).
查看详情 查看详情
21
2022-01

New drug for Parkinson's disease (PD)! NE3107 enters phase 2 clinical: showed higher prokinetic activity in combination with levodopa!

Time of issue: : 2022-01--21
NE3107 is an oral, blood-brain barrier-crossing small molecule compound with anti-inflammatory, insulin-sensitizing and ERK-binding properties.
查看详情 查看详情
21
2022-01

The world's first BCMA CAR-T therapy! Bristol-Myers Squibb's Abecma (ide-cel) approved in Japan: treatment of multiple myeloma!

Time of issue: : 2022-01--21
Abecma is the world's first marketed BCMA-directed CAR-T cell therapy.
查看详情 查看详情
21
2022-01

Lung cancer "targeted + immune" first-line treatment! Gilead and Merck Collaborate: Develop Trodelvy+Keytruda Combination Therapy!

Time of issue: : 2022-01--21
Trodelvy is an antibody-drug conjugate targeting Trop-2, and Keytruda is an anti-PD-1 tumor immunotherapy.
查看详情 查看详情
Previous page
1
2

Tel

0717-6855399

Whatapp

15377615856 

E-mail

sales@sndswyy.cn

TOP

Home
About Us
Company Profile Culture Environmental Patented Honor
Product
Material intermediate Scientific research original drug series Advanced Pharmaceutical Intermediates
Patented
News
Careers
Talent Concept Recruitment
Contact

CONTACT

Contact: Mr. Lu
Tel：0717-6855399   15377615856
QQ：2710885149
E-mail：sales@sndswyy.cn
Add：Building 7, No. 519, Juxiang Road, Wujiagang, Yichang City, Hubei Province

 Copyright   2022 Yichang Shangnuode Biomedical Technology Co., Ltd. All rights reserved SEO label  鄂ICP备2021022125号-1